NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

May 08, 2028
Response Due
Active
Status

Opportunity Overview

This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC). The overall goal is to move from simply cataloguing genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to Mechanism with potential applications of AI and ML tool sets where possible, enabling functional genomics research that will accelerate mechanistic personalized medicine

This is one of 1,273 active United States Health Services opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryHealth Services
NAICS93.837, 93.838, 93.8
PublishedSeptember 22, 2025
Procurement stageRequest for Proposal (RFP)
Response dueMay 08, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: U.S. Government (Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed)
NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
NIH Director’s New Innovator Award (DP2 Clinical Trial Optional)
Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)

See every United States Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Health Services intelligence report in your inbox

A personalized report on United States Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.